Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Leber hereditary optic neuropathy in Czechia and Slovakia: Quality of life and costs from patient perspective

B. Bušányová, M. Vajter, S. Kelifová, P. Lišková, H. Miková, K. Breciková, J. Žigmond, V. Rogalewicz, A. Tichopád, M. Višňanský, I. Šarkanová

. 2024 ; 10 (11) : e32296. [pub] 20240531

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018356

INTRODUCTION: Leber hereditary optic neuropathy (LHON) is the most frequent mitochondrial disease causing dyschromatopsia and progressive central visual loss that is subacute in progression and painless. Several studies have been published assessing QoL in patients with LHON, but no estimate of the economic burden has been reported to date. This study aims to quantify direct non-medical and indirect costs (productivity loss) incurred by LHON patients and their informal caregivers in Czechia and Slovakia, as well as to assess their quality of life. METHODS: The study was performed in 27 adults and children with LHON. To determine the socioeconomic burden of LHON, separate questionnaires for adults, children, and their parents were developed, including demographic and socioeconomic data. The following data were collected: age, education, family size, severity of LHON, non-medical direct and indirect costs of LHON. RESULTS: The mean age of adult respondents was 36.1 years (SD 13.1; n = 21). The total cost of absenteeism was EUR 1003 per person/year in adult employees, and EUR 2711 per person/year in children's parents. The productivity loss as a consequence of LHON due to combined relative absenteeism and relative presenteeism was estimated at EUR 9840 per an adult patient/year, and EUR 6298 per a parent/year, respectively. The mean cost of informal care was estimated at EUR 4502 (SD 4772; n = 6) per person/year. The mean VFQ-25 score for adult patients with LHON was 43.47 (SD 15.86). CONCLUSION: The results of this study clearly show that patients with LHON and their families face an extensive socioeconomic burden related to this rare disease. Early, timely and appropriate access to diagnosis, treatment, and reimbursement decisions, but also to psychological counselling and services may help the patients and their relatives adapt and cope with the challenging aspects of vision loss and life with the disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018356
003      
CZ-PrNML
005      
20241127145709.0
007      
ta
008      
241008s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.heliyon.2024.e32296 $2 doi
035    __
$a (PubMed)38961918
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bušányová, Beáta $u Department of Paediatric Ophthalmology of the Faculty of Medicine, Comenius University Bratislava, And the National Institute of Children's Diseases in Bratislava, Slovakia
245    10
$a Leber hereditary optic neuropathy in Czechia and Slovakia: Quality of life and costs from patient perspective / $c B. Bušányová, M. Vajter, S. Kelifová, P. Lišková, H. Miková, K. Breciková, J. Žigmond, V. Rogalewicz, A. Tichopád, M. Višňanský, I. Šarkanová
520    9_
$a INTRODUCTION: Leber hereditary optic neuropathy (LHON) is the most frequent mitochondrial disease causing dyschromatopsia and progressive central visual loss that is subacute in progression and painless. Several studies have been published assessing QoL in patients with LHON, but no estimate of the economic burden has been reported to date. This study aims to quantify direct non-medical and indirect costs (productivity loss) incurred by LHON patients and their informal caregivers in Czechia and Slovakia, as well as to assess their quality of life. METHODS: The study was performed in 27 adults and children with LHON. To determine the socioeconomic burden of LHON, separate questionnaires for adults, children, and their parents were developed, including demographic and socioeconomic data. The following data were collected: age, education, family size, severity of LHON, non-medical direct and indirect costs of LHON. RESULTS: The mean age of adult respondents was 36.1 years (SD 13.1; n = 21). The total cost of absenteeism was EUR 1003 per person/year in adult employees, and EUR 2711 per person/year in children's parents. The productivity loss as a consequence of LHON due to combined relative absenteeism and relative presenteeism was estimated at EUR 9840 per an adult patient/year, and EUR 6298 per a parent/year, respectively. The mean cost of informal care was estimated at EUR 4502 (SD 4772; n = 6) per person/year. The mean VFQ-25 score for adult patients with LHON was 43.47 (SD 15.86). CONCLUSION: The results of this study clearly show that patients with LHON and their families face an extensive socioeconomic burden related to this rare disease. Early, timely and appropriate access to diagnosis, treatment, and reimbursement decisions, but also to psychological counselling and services may help the patients and their relatives adapt and cope with the challenging aspects of vision loss and life with the disease.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vajter, Marie $u Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Kelifová, Silvie $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Lišková, Petra $u Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Miková, Hedviga $u Ophthalmological Outpatient Clinic, University Hospital - St. Michael's Hospital, Bratislava, Slovakia
700    1_
$a Lejavová, Katarína, $u CEEOR s.r.o, Prague, Czech Republic $d 1987- $7 xx0326522
700    1_
$a Žigmond, Ján $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic
700    1_
$a Rogalewicz, Vladimír $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic
700    1_
$a Tichopád, Aleš $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic
700    1_
$a Višňanský, Martin $u Department of Pharmacy and Social Pharmacy, University of Veterinary Medicine and Pharmacy in Košice, Slovakia $u Department of Public Economics, Faculty of Economics and Administration, Masaryk University in Brno, Czech Republic
700    1_
$a Šarkanová, Ivana $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic $7 xx0326508
773    0_
$w MED00190064 $t Heliyon $x 2405-8440 $g Roč. 10, č. 11 (2024), s. e32296
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38961918 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241008 $b ABA008
991    __
$a 20241127145704 $b ABA008
999    __
$a ok $b bmc $g 2196537 $s 1230309
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 10 $c 11 $d e32296 $e 20240531 $i 2405-8440 $m Heliyon $n Heliyon $x MED00190064
LZP    __
$a Pubmed-20241008

Najít záznam

Citační ukazatele

Možnosti archivace